0001209191-18-057771.txt : 20181108 0001209191-18-057771.hdr.sgml : 20181108 20181108170324 ACCESSION NUMBER: 0001209191-18-057771 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181106 FILED AS OF DATE: 20181108 DATE AS OF CHANGE: 20181108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lloyd-Smith Malcolm CENTRAL INDEX KEY: 0001557146 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 181170482 MAIL ADDRESS: STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-06 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001557146 Lloyd-Smith Malcolm 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Regulatory Officer Common Stock 2018-11-06 4 M 0 5700 15.45 A 21018 D Common Stock 2018-11-06 4 S 0 5700 110.0168 D 15318 D Common Stock 2018-11-07 4 M 0 3300 15.45 A 18618 D Common Stock 2018-11-07 4 S 0 3300 110.00 D 15318 D Non-Qualified Stock Option 15.45 2018-11-06 4 M 0 5700 15.45 A 2024-10-01 Common Stock 5700 13256 D Non-Qualified Stock Option 15.45 2018-11-07 4 M 0 3300 15.45 A 2024-10-01 Common Stock 3300 9956 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Option granted October 1, 2014 and vested 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015. /s/ Darin Lippoldt, Attorney-in-Fact 2018-11-08